Tilray | TRLY - Selling And Administration Expenses


Tilray reported $24.85M in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
Acasti Pharma USD 1.96M 180K Sep/2025
Akebia Therapeutics USD 23.53M 3.19M Dec/2025
Alaunos Therapeutics USD 447K 138K Mar/2026
Aurora Cannabis CAD 40.62M 1.17M Dec/2025
Avita Medical AUD 19.03M 1.95M Dec/2025
Canopy Growth CAD 28.9M 636K Dec/2025
Cronos Group USD 17.35M 2.1M Mar/2026
Dianthus Therapeutics USD 6.57M 1.62M Dec/2025
Divis Laboratories Ltd INR 3.4B 10M Jun/2025
Ionis Pharmaceuticals USD 151M 21M Mar/2026
IQVIA Holdings USD 502M 34M Mar/2026
Knight Therapeutics CAD 35.45M 4.43M Dec/2025
Moderna USD 173M 135M Mar/2026
Organigram Holdings CAD 7.73M 1.13M Dec/2025
Organon & Co USD 433M 34M Dec/2025
Revvity USD 253.88M 2.15M Mar/2026
Tectonic Therapeutic USD 3.44M 1.52M Dec/2025
Tilray USD 24.85M 1.7M Sep/2025
Viatris USD 928.8M 101.9M Mar/2026
Xeris Pharmaceuticals USD 42.64M 3.82M Dec/2025
Zealand Pharma A/S 91.81M 99.04M Dec/2025